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Abstract: Locally advanced thyroid cancer exhibits aggressive clinical features requiring extensive
neck dissection. Therefore, it is important to identify changes in the tumor biology before local
progression. Here, whole exome sequencing (WES) using tissues from locally advanced papillary
thyroid cancer (PTC) presented a large number of single nucleotide variants (SNVs) in the metastatic
lymph node (MLN), but not in normal tissues and primary tumors. Among those MLN-specific
SNVs, a novel HHIP G516R (G1546A) mutation was also observed. Interestingly, in-depth
analysis for exome sequencing data from the primary tumor presented altered nucleotide ‘A’ at
a very low frequency indicating intra-tumor heterogeneity between the primary tumor and MLN.
Computational prediction models such as PROVEAN and Polyphen suggested that HHIP G516R
might affect protein function and stability. In vitro, HHIP G516R increased cell proliferation and
promoted cell migration in thyroid cancer cells. HHIP G516R, a missense mutation, could be
a representative example for the intra-tumor heterogeneity of locally advanced thyroid cancer,
which can be a potential future therapeutic target for this disease.
Keywords: hedgehog proteins; neoplasm invasiveness; thyroid cancer
1. Introduction
Thyroid cancer is the most common endocrine malignancy and is associated with an excellent
long-term prognosis [1]. However, in a significant number of patients with papillary thyroid cancer
(PTC), the disease displays a more aggressive behavior, including locoregional recurrence frequently
associated with metastatic lymph node metastasis (LNM) [2,3]. In line with these observational
data, prediction of LNM in patients with PTC has emerged as a research field in thyroid cancer.
Moreover, in addition to clinicopathological poor prognostic parameters, molecular markers easily
applied to fine-needle aspiration biopsy (FNAB) samples have been extensively investigated to
determine the surgical extent, such as in prophylactic central lymph node dissection (CLND) [3–5].
Currently, the BRAFV600E mutation is the most useful diagnostic and prognostic molecular marker in
Int. J. Mol. Sci. 2018, 19, 2867; doi:10.3390/ijms19102867 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 2867 2 of 11
patients with PTC for predicting occult lymph node metastasis [5]. Actually, several meta-analyses
recently reported an overall correlation of the BRAFV600E mutation with extra-thyroidal extension
(ETE) and LNM [6,7]. However, the results across individual studies are inconsistent, and several
similar large retrospective trials have failed to corroborate these results [8,9]. Therefore, the overall
significance of the BRAFV600E mutation remains under debate.
Whole-exome sequencing (WES), a next-generation sequencing (NGS) technology, is an efficient
approach to selectively identify cancer mutations in the coding regions of the genome, allowing the
identification of potential causative alterations in unexpected genes. Although, compared to whole-
genome sequencing (WGS), WES cannot identify most intronic and regulatory regions, it improves
sequencing coverage and depth for coding regions, thus providing high sensitivity for uncovering even
low-frequency mutations, as recently implemented by The Cancer Genome Atlas (TCGA) NIH project
(http://cancergenome.nih.gov/). Thus, for basic research and molecular diagnostic applications,
WES is currently the best NGS strategy considering its extensiveness, time required, and cost [10,11].
The Hedgehog (HH) signaling pathway was originally identified as a crucial pathway in embryonic
patterning and development [12]. The central components of the mammalian HH pathway consist
of three secretory ligands (Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog
(DHH)); a 12-pass transmembrane receptor involved in the negative regulation of the pathway,
Patched1 (PTCH1); a negative regulator, Hedgehog interacting protein (HHIP); a G-protein-coupled
receptor like seven-pass transmembrane protein, Smoothened (SMO); and three transcription factors
(GLI1, GLI2, and GLI3) [12]. Aberrant activation of the HH pathway has been linked to tumorigenesis
in medulloblastoma [13] and basal cell carcinoma [14]. Moreover, hyperactive HH signaling has been
identified in lymphoma, breast, prostate, colorectal, liver, stomach, and small cell lung cancers, as well
as multiple myeloma and chronic myeloid leukemia [15,16]. Recently, the pathway was reported to be
associated with thyroid cancer cell proliferation and invasiveness [17,18]. However, the role of HHIP
in cancer is poorly understood, although it is well known that inactivating mutations in PTCH1 or
Suppressor of fused homolog (SUFU) or activating mutations in SMO contribute to tumorigenesis
through HH signaling activation [19,20].
Here, we performed WES of three locally advanced PTC cases, including normal tissue,
the primary tumor, and metastatic lymph nodes, to identify additional driver mutations as well
as mutations potentially facilitating tumor progression, such as LNM. We found a novel HHIP G516R
mutation in the metastatic lymph node (MLN) and predicted the mutation-induced functional changes
in HHIP, including protein function and physical properties, using several computational models for
the functional effects of single nucleotide variants (SNVs). In addition, we observed the biological
effects of this mutation on thyroid cancer cell properties in vitro.
2. Results
2.1. Spectrum and Characteristics of Somatic Mutations
The baseline characteristics of patients with PTC subjected to WES are summarized in Table S1.
The total number of detected insertion, deletion, and single nucleotide variants (SNVs) and the
numbers of common and sample-specific somatic insertions, deletions, and SNVs in primary tumors
or metastatic lymph nodes are presented in Figure S1. The proper read rates ranged from 87.48 to
91.77%, and the properly paired rates ranged from 98.63% to 98.89%. A mean coverage depth of
108.7× per sample was achieved, with 89.2% of targets covered at a depth of ≥20×. In all samples,
C > T/G > A/T > C/A > G transitions were dominant in the SNV substitution spectrum (70.46–71.24%
of all mutations, Figure 1A), and the percentage of missense SNVs in all exon SNVs ranged from 46.22
to 47.31% (Figure 1B). Next, we calculated the number of somatic SNVs in primary tumors (PLM01-2,
PLM02-2, and PLM03-2) and metastatic lymph nodes (PLM01-3 (level VI), PLM01-4 (level II), PLM02-3
(level IV), PLM03-3 (level VI), and PLM03-4 (level IV)) by removing common SNVs detected in
each corresponding normal tissue (PLM01-1, PLM02-1, and PLM03-1). In this analysis, we found
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139 common somatic SNVs among PLM01-2, PLM01-3, and PLM01-4 (Figure 1C) and 154 common
somatic SNVs between PLM02-2 and PLM02-3 (Figure 1D). In case 3, we found 91 common somatic
SNVs among PLM03-2, PLM03-3, and PLM03-4 (Figure 1E). The number of variants across the samples
was independent of disease stage. Notably, we identified novel tumor- or lymph node-specific somatic
mutations (Tables S2–S5 and Figure S2A).
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2.2. A Novel Hedgehog Interacting protein (HHIP) G516R Mutation in Metastatic Lymph Nodes 
Among the gene list of novel somatic mutations in tumors or lymph nodes, we focused on a 
novel G1546A mutation in HHIP because its Polymorphism Phenotyping v2 (PolyPhen-2, 
http://genetics.bwh.harvard.edu/pph2/) and Protein Variation Effect Analyzer (PROVEAN, 
http://provean.jcvi.org/index.php) scores were highest among newly detected point mutations 
(Figure 2A and Table S6). This missense mutation is in HHIP exon 9, resulting in the substitution of 
glycine by arginine at position 516 (G516R). To verify the presence of the HHIP G1546A mutation, we 
performed pyrosequencing representing the mutant nucleotide “A” significantly on pyrograms 
using genomic DNA samples derived from MLN (PLM01-3 and PLM01-4) but not from normal and 
primary tumor tissues showing non-specific “A” peak below 5 percent (PLM01-1 and PLM01-2) 
(Figure S2). Interestingly, even though our WES analysis and pyrogram did not show the HHIP 
G1546A mutation in PLM01-2, an in-depth analysis indicated the mutant nucleotide “A,” suggesting 
that a small proportion of tumor cells might harbor the HHIP G1546A mutation (Figure S3) and 
indicating intra-tumor heterogeneity among genetically defined subclones. The 516 site was 
conserved among all vertebrate HHIP sequences queried (Figure 2B), but not in Xenopus and 
Drosophile, substantiating it as an evolutionary acquisition residue (Clustalw2, 
http://www.ebi.ac.uk/Tools/msa/clustalw2/). As listed in Table S6, PROVEAN predicted that G516R 
substitution affects protein function based on sequence homology and the physical properties of 
amino acids. Remarkably, the PROVEAN score was −6.833, definitely below the predefined threshold 
(−2.5), predicting a “deleterious effect” of the G516R mutation (Figure 2C). Moreover, PolyPhen-2 
also indicated that the G516R mutation has probably been damaged, with a score of 1.000 (Specificity 
= 1.00, Figure 2C). I-MUTANT2.0 and I-MUTANT3.0 (http://folding.biofold.org/i-mutant/) suggested 
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(C), PLM02 (D), and PLM03 (E).
2.2. A Novel Hedgehog Interacting protein (HHIP) G516R Mutation in Metastatic Lymph Nodes
Among the gene list of novel so atic mutations in tumors or lymph nodes, we focused
on a novel G1546A mutation in HIP because its Poly orphis Phenotyping v2 (PolyPhen-2,
http://genetics.b h.harvard.edu/pph2/) and Protein Variation Effect Analyzer (PROVEAN,
http://provean.jcvi.org/index.php) scores ere highest a ong newly detected point mutations
(Figure 2A and Table S6). This missense mutation is in HHIP exon 9, resulting in the substitution of
glycine by arginine at position 516 (G516R). To verify the presence of the HHIP G1546A mutation,
we performed pyrosequencing representing the utant nucleotide “A” significantly on pyrograms
using genomic DNA sa ples derived fro L (PLM01-3 and PLM01-4) but not from normal
and primary tumor tissues showing non-specific “A” peak belo 5 percent (PL 01-1 and PLM01-2)
(Figure S2). Interestingly, even though our WES analysis and pyrogram did not show the HHIP G1546A
mutation in PLM01-2, an in-depth analysis indicated the mutant nucleotide “A,” suggesting that a
small proportion of tumor cells ight harbor the HHIP G1546A mutation (Figure S3) and indicating
intra-tumor heterogeneity among genetically defined subclones. The 516 site was conserved among all
vertebrate HHIP sequences queried (Figure 2B), but not in Xenopus and Drosophile, substantiating it
as an evolutionary acquisition residue (Clustalw2, http://www.ebi.ac.uk/Tools/msa/clustalw2/).
As listed in Table S6, PROVEAN predicted that G516R substitution affects protein function based on
sequence homology and the physical properties of amino acids. Remarkably, the PROVEAN score was
−6.833, definitely below the predefined threshold (−2.5), predicting a “deleterious effect” of the G516R
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mutation (Figure 2C). Moreover, PolyPhen-2 also indicated that the G516R mutation has probably been
damaged, with a score of 1.000 (Specificity = 1.00, Figure 2C). I-MUTANT2.0 and I-MUTANT3.0
(http://folding.biofold.org/i-mutant/) suggested that the G516R mutation might affect protein
stability and be a disease-related mutation (DDG value = −0.85, Table S6). Computational analysis
of the HHIP extracellular domain (ECD) sequence revealed four globular domains: a cysteine-rich
N-terminal domain with a Frizzled (Fz) fold, a central six-bladed β-propeller, and two C-terminal
EGF repeats. The 516 residue is on the β-propeller domain, and the substitution of glycine by arginine
changes the hydropathy index from −0.4 to −4.5 and allows the possession of a long side chain
(Figure 2D). In summary, the HHIP G516R mutant was predicted to severely affect the protein structure
and function.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 11 
 
that he G516R mutation might affect protein stability and be a disease-related m tation (DDG value 
= −0.85, Table S6). Computational analysi  of the HHIP extracellular domain (ECD) equenc  revealed 
fou  globular domains:  cysteine-rich N-terminal domain with a Frizzled (Fz) fold, a central six-
blad d β-prop ller, and two C-terminal EGF repeats. The 516 r sidue is on the β-propeller domain, 
and the substitution of glycine by arginine changes the hydropat y index fr m −0.4 t  −4.5 and allows 
the possession of a long side chain (Figure 2D). In summary, the HHIP G516R mutant was predict d 
to severely affect the protein structure and function. 
 
Figure 2. Analysis of novel tumor or metastatic lymph node-specific SNVs. (A) Five representative 
SNVs; (B) Sequence alignment of HHIP mutation sites in various species. The arrow indicates the 
amino acid at the site where the mutation was found in this study; (C) Results of PROVEAN and 
PolyPhen analyses of HHIP G516R; (D) Comparison of computational modeling between HHIP WT 
and HHIP G516R. Red color also indicates the amino acid at the site where the mutation was found 
in this study. 
2.3. HHIP Expression as a Marker of Hedgehog Signal Activation in Human Thyroid Cancer 
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anti-FLAG antibody and detect an HA signal in precipitated pellets by western blot analysis (See 
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SHH-HA. Interestingly, SHH-HA band intensity was not decreased in HHIP G516R transfected 
pellets compared to HHIP WT transfected pellets, indicating the HHIP-G516R mutant did not make 
any disturbance of the interaction with SHH compared to HHIP-WT (Figure 3). The other interesting 
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HHIP-WT transfected lysates (Figures 3 and S4), indicating interaction of the G516R mutant protein 
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Figure 2. Analysis of novel tumor or metastatic lymph node-specific SNVs. (A) Five representative
SNVs; (B) Sequence alignment of HHIP mutation sites in various species. The arrow indicates the
amino acid at the site where the mutation was found in this study; (C) Results of PROVEAN and
PolyPhen analyses of HHIP G516R; (D) Comparison of computational modeling between HHIP WT
and HHIP G516R. Red color also indicates the amino acid at the site where the mutation was found in
this study.
2.3. HHIP Expression as a Marker of Hedgehog Signal Activation in Human Thyroid Cancer
Because HHIP is a well-known binding partner of SHH and the HHIP G516R mutant was predicted
to severely affect the protein structure and function, we decided to perform co-immunoprecipitation
assay using SHH-HA, FLAG-HHIP-WT, and FLAG-HHIP-G516R. First we transfected 8505C cells with
indicated plasmids for 24 h and conducted co-immunoprecipitation with anti-FLAG antibody and
detect an HA signal in precipitated pellets by western blot analysis (See Materials and Methods in detail)
to see the impact of HHIP-G516R mutation on the interaction with SHH-HA. Interestingly, SHH-HA
band intensity was not decreased in HHIP G516R transfected pellets compared to HHIP WT transfected
pellets, indicating the HHIP-G516R mutant did not make any disturbance of the interaction with SHH
compared to HHIP-WT (Figure 3). The other interesting finding was that the FLAG signal was much
higher in HHIP G516R transfected lysates compared to HHIP-WT transfected lysates (Figure 3 and
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Figure S4), indicating interaction of the G516R mutant protein with SHH might increase the HHIP
protein amount in thyroid cancer cells.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 11 
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2.4. HHIP G516R Mutation Promotes Thyroid Cancer Cell Proliferation and Migration
Although our computational modeling indicated HHIP G516R mutation can affect the protein
structure and function, we could not find any disturbance of interaction between HHIP G516R with
SHH disappointingly. Next, we determined to investigate the functional effect of the HHIP G516R
mutation on thyroid cancer cell properties to understand the biological role of this mutation in human
thyroid cancer. To achieve this goal, we transfected 8505C cells with FLAG-HHIP WT and HHIP
G516R mutant plasmid as indicated (Figure 4 and Figure S5). To observe the effect of the HHIP
G516R mutation on proliferation, 8505C cells were analyzed by cell counting 72 h after the respective
transfection. As expected, the HHIP G516R mutation significantly promoted cell proliferation even
though the overexpression of HHIP-WT did not have any effect (Figure 4A,B and Figure S5). We next
performed a wound-healing/migration assay to investigate the effect of the HHIP G516R mutation on
thyroid cancer cell behavior. Interestingly, 12 or 24 h after the monolayers were scratched, the sizes
of the wounds were significantly smaller in 8505C cells transfected with HHIP-G516R than in cells
transfected with the control vector or HHIP-WT (Figure 4C,D and Figure S5), indicating that the HHIP
G516R mutation promotes thyroid cancer cell migration. All these data indicate that the HHIP G516R
mutation promotes tumor aggressiveness in thyroid cancer compared to HHIP-WT.
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3. Discussion
In this study, we identified the novel HHIP G516R mutation by performing WES of locally
advanced thyroid cancer tissues, including primary tumors and metastatic lymph nodes. This mutation
was predic e to have severe detrim ntal effects on HHIP function. In fact, in vitr experiments showed
that HHIP G516R promoted thyroid cancer cell proliferation and migration.
Of note, our pyrosequencing and in-depth analysis suggested that acquisition of intra-tumor
heterogeneity might be a crucial process for tumor progression. Cancers contain numerous clones
with various population sizes, different genetic development, and distinct phenotypic features [21,22].
This intra-tumor heterogeneity drives carcinogenesis and tumor progression and contribute to
therapeutic failure and acquired drug resistance [21]. WES, which is currently one of the best
NGS strategies considering its cost-effectiveness, is a powerful analysis for unraveling the clonal
heterogeneity, evolution, and potential for competitive generation of resistant subclones [23].
Here, the proportion of mutant nucleotide A (HHIP G516R mutation) was much higher in metastatic
lymph nodes than in primary tumors (Figure S2B–D, 3.5% versus 15.4% or 25.8%). In fact, 3.5% is
below the positive cut-off value for pyrosequencing. Furthermore, the in-depth analysis demonstrated
that the mutant n cleotide A exist d in primary tumors although WES analysis could not identify the
HHIP G1546A muta ion (Figure S3). These findings suggest that a small population of tumor cells
harboring a specific mutation lik HHIP G1546A could evolve during the invasion a d metas atic
process, as indicated by the increased proportion of mutant nucleotide A.
Aberrant activation of HH signaling is closely related to several types of cancer, although this
pathway is crucial for many steps in embryonic development [19]. Similar to PTCH1, HHIP is a
negative regulator of the HH pathway and is equipotent against three mammalian HH ligands, SHH,
IHH, and DHH [24]. According to a recent study, HHIP competitively binds at the SHH pseudo-active
site against PTCH1, thereby inhibiting the HH pathway [25]. Our computational modeling suggested
that HHIP G516R might have significant structural changes induced by the single amino acid
substitution, being predicted to affect protein-to-protein interactions. However, the interaction of
HHIP with SHH was not affected by G516R substitution in our co-immunoprecipitation (co-IP)
assay. We understand that this negative co-IP data indicated that a non-canonical pathway ight
be operational in PTC harboring HHIP G516R because this novel mutation was able to increase
cell proliferation a d migration even though HHIP WT has no effect on these tumor cell pheno ypes.
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In general, decreased HHIP expression has been indicated in several tumors, suggesting a potential role
of HHIP in tumor suppression [26]. Several recent studies reported that HHIP is hypermethylated and
transcriptionally down-regulated in some cancers and mouse models [27,28]. However, our western
blot data also indicated that the amount of HHIP G516R protein was not decreased, compared to HHIP
WT protein. This finding could also be evidence supporting the existence of a non-canonical pathway
operated by mutant HHIP G516R.
Our study has some limitations. Firstly, because of the small number of tumor samples,
the findings from this study need to be validated in future studies. However, our study might
be a representative model to suggest the presence of intra-tumor heterogeneity in locally advanced
thyroid cancers. In addition, the functional study of mutant HHIP G516R in this paper was only
performed by transient transfection technology. Although the direct effect of mutant protein can
be best investigated using this technique, the long-term effects of mutant HHIP G516R also need to
be validated. Despite this, the mutation was detected in human locally advanced thyroid cancers,
which might suggest the long-term effect of mutant HHIP G516R. Thirdly, although our data indicated
the existence of intra-tumor heterogeneity, novel technology platforms such as the study of genomics,
transcriptomics, proteomics, and metabolomics at the single cell level will shed light on the poorly
understood areas in this field.
In conclusion, WES indicated intra-tumor heterogeneity in locally advanced thyroid cancers.
In addition, this study first identified HHIP G516R (G1546A), which promotes tumor aggressiveness
in thyroid cancer cells.
4. Materials and Methods
4.1. Whole Exome Sequencing
Tissue samples from three patients with locally advanced PTC were obtained by surgery for DNA
extraction in April 2014. The tissues were collected in cryogenic tubes and were stored at −20◦C in
DNAlater solution (Thermo Fisher Scientific, Inc., Waltham, MA, USA). DNA extraction was performed
using the QiaAmp DNA Mini kit (Qiagen, Inc., Valencia, CA, USA). Eleven samples were analyzed by
WES, performed at 200 × 2 bp on a HiScanSQ Illumina platform (Illumina, Inc., San Diego, CA, USA).
The cleaned reads were mapped to the human reference genome hg38 using Burrows–Whealer Aligner
in paired-end mode [29]. To remove the optical and PCR duplicates and optimize the alignment
around InDels, Samtools and GATK were used [30,31]. Single nucleotide variants (SNVs) and InDels
were detected using GATK (HaplotypeCaller mode), Mutect, and SNVmix2 [32,33]. The whole
set of detected variants was refined filtering threshold for each sample, based on the presence
and relative enrichment of the BRAFV600E mutation; only samples with >10% tumor vs. normal
allele were included in the study. The obtained variants were annotated with 1000 Genomes allele
frequencies, dbSNP 149 rsIDs, Exac, and EVS using Annovar and Oncotator [34,35]. Finally, to predict
the pathogenic significance of the emerging variants, mutation-prediction tools (PolyPhen2, Proven
and SIFT) were used [36–38]. Patient information and clinicopathological parameters were analyzed
retrospectively. Written informed consent was obtained from the patients and all protocols were
approved by the institutional review board of Severance Hospital (The approval number, 4-2013-0546;
The approval date, 7 April 2013).
4.2. Pyrosequencing
Pyrosequencing to verify the HHIP G516R mutation in tissue samples was performed as
previously described [39]. Briefly, A 5-µL volume of the genomic DNA was amplified by PCR
using standard conditions (95 ◦C: 5 min; 94 ◦C: 30 s, 68 ◦C: 30 s, 72 ◦C: 30 s, for 32 cycles; 70 ◦C:
10 min) with the following primers: forward 5′-GAA GCT ACG TGT TTG GAG ATC G-3′ and reverse
5′ biotin-GCA GTT TGC CAA ATG ATT AAT G-3′. After immobilizing the resulting PCR products
onto magnetic streptavidin-coated beads (Magnetic Biosolutions, Stockholm, Sweden), the bead/DNA
Int. J. Mol. Sci. 2018, 19, 2867 8 of 11
complex was washed to remove unwanted components. A pyrosequencing primer (5′-CGT GTT
TGG AGA TCG TA-3′) was added and annealed to the captured strand following the manufacturer’s
instructions (Magnetic Biosolutions) with Magnatrix 1200 robot (Magnetic Biosolutions). The primed
single-stranded DNA templates were transferred to a PSQ HS 96 A Pyrosequencer (Biotage,
Uppsala, Sweden).
4.3. Computational Analysis of the HHIP Extracellular Domain
The protein sequence of human HHIP (NP_071920.1) was obtained from NCBI Human Genome
Resources (http://www.ncbi.nlm.nih.gov/protein). Computational models were generated using
MODELLER [40], and a reliable structure was selected by PROCHECK analysis [41]. The predicted
model quality was checked assessed by Ramachandran plot analysis [42].
4.4. Cell Culture
The 8505C human thyroid cancer cell line was kindly provided by Peter A Kopp (Northwestern
University, Chicago, IL, USA). 8505C cells were cultured in RPMI-1640 (Corning, VA, USA) media
containing 10% fetal bovine serum and 1% penicillin/streptomycin in a humidified atmosphere of 5%
CO2 and 95% air at 37 ◦C.
4.5. Transfection of HHIP Wild-Type and G516R Mutant Plasmids
pcDNA3.1-FLAG-HHIP wild-type (WT) was purchased from Origene (Rockville, MD, USA),
and pcDNA3.1-FLAG-HHIP-G516R mutant plasmid was generated by Site-Directed Mutagenesis Kits
according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). To determine
the effects of the HHIP G516R mutation on cancer cell properties, 8505C cells were transfected with
pcDNA3.1 control vector, pcDNA3.1-FLAG-HHIP WT, or pcDNA3.1-FLAG-HHIP G516R mutant using
Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA). The cells were analyzed by western
blotting, cell counting, and wound healing/migration assay 48 or 72 h after the transfection.
4.6. Western Blot Analysis
Cells were washed once with ice-cold PBS and immediately lysed with cell extraction buffer
(FNN0011, Invitrogen) and EDTA-free protease inhibitor (1 tablet per 25 mL buffer, Roche, Basel,
Switzerland). The cell lysates were incubated at 4 ◦C for 30 min and cleared by centrifugation at
13,000 rpm at 4 ◦C for 10 min. Then, 20–30 µg of proteins from the cell lysates was prepared, resolved on
8% SDS-PAGE gels, and transferred to PVDF membranes. The membranes were probed with antibodies
against FLAG (A8592, Sigma, St. Louis, MO, USA), HA (3724S, Cell Signaling, Danvers, MA, USA),
and β-actin (sc-47778, Santa Cruz Biotechnology, Inc., Dallas, TX, USA).
4.7. Co-Immunoprecipitation Assay
For co-immunoprecipitation (IP) assays to evaluate the interaction between FLAG-HHIP
and SHH-HA, we first transfected 8505C cells with SHH-HA and/or FLAG-HHIP-WT,
or FLAG-HHIP-G516R plasmid as indicated. After 24 h incubation at normal culture condition,
the cell extracts from the transfected cells were cleared by centrifugation at 13,000 rpm at 4 ◦C for
10 min, and the supernatants were incubated with anti-FLAG antibody (F1804, Sigma) for 12 h at
4 ◦C under gentle agitation. In order to isolate the protein complex binding with anti-FLAG antibody,
protein A/G PLUS-Agarose (sc-2003, Santa Cruz) was then added to each sample, and the mixtures
were incubated overnight at 4 ◦C on a rotating device. Immunoprecipitates formed by this process were
collected by centrifugation at 1000× g for 5 min at 4 ◦C and washed three times with PBS. The pellets
were eluted by heating at 95 ◦C for 5 min in 1× electrophoresis sample buffer for western blot analysis
as indicated.
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4.8. Wound Healing/Migration Assay
8505C cells were seeded in 6 well culture plates and allowed to form a confluent monolayer.
A scratch wound was made with a 1000 µL pipette tip. The cells were then washed with PBS to
remove cell debris. Microscopic images were obtained 0, 12, and 24 h after scratching. The sizes of the
wounds were measured using Image J software (https://imagej.nih.gov/ij/). The data are shown as a
percentage of the initial size. The assay was performed in quadruplicate in each condition.
4.9. Statistical Analysis
Continuous variables were compared using two-tailed Student’s t test, and categorical data were
compared using the x2 test or Fisher’s exact test. Statistical analyses were performed using SPSS
software for Windows (Version 23; IBM Corp., New York, NY, USA) or GraphPad Prism 6 (GraphPad
Software Inc., San Diego, CA, USA). p values less than 0.05 were considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/
2867/s1.
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